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Abstract
Background: There is ethnopharmacological evidence that Petiveria alliacea can have antitumor
activity; however, the mechanism of its cytotoxic activity is not well understood. We assessed
multiple in vitro biological activities of an ethyl acetate soluble plant fraction over several tumor cell
lines.
Methods: Tumor cell lines were evaluated using the following tests: trypan blue exclusion test,
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide], flow cytometry,
cytoskeleton organization analysis, cell cycle, mitochondria membrane depolarization,
clonogenicity test, DNA fragmentation test and differential protein expression by HPLC-Chip/MS
analysis. F4 fraction characterization was made by HPLC-MS.
Results:  Petiveria alliacea fraction characterized by de-replication was found to alter actin
cytoskeleton organization, induce G2 cell cycle arrest and cause apoptotic cell death in a
mitochondria independent way. In addition, we found down regulation of cytoskeleton, chaperone,
signal transduction proteins, and proteins involved in metabolic pathways. Finally up regulation of
proteins involved in translation and intracellular degradation was also observed.
Conclusion: The results of this study indicate that Petiveria alliacea exerts multiple biological
activities in vitro consistent with cytotoxicity. Further studies in animal models are needed but
Petiveria alliacea appears to be a good candidate to be used as an antitumor agent.
Background
Inherent or acquired resistance can occur simultaneously
to multiple drugs in the majority of tumor cells [1-4].
Almost 40% of cancer patients with resectable and 80%
with unresectable disease have a reduced response to
chemotherapy and radiotherapy. Several mechanisms
have been associated with this resistance [5] and in order
to overcome it, search for new antitumor agents must tar-
get different cell components within the tumor cell. In
fact, single antitumoral compounds may be ineffective
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because of their unique molecular target. Therefore, pres-
ence of multiple compounds in well characterized plant
extract with synergic activities, may tackle this difficulty
since agonist or additive functions may emerge.
Petiveria alliacea L. (Phytolaccaceae) is a perennial shrub
indigenous to the Amazon Rainforest, although it can
grow in areas as Tropical and Central America, Caribbean
and Southeastern United States. In folk medicine, Petiveria
alliacea, is used to treat a wide variety of disorders. Root in
decoction, powder or leaves infusion are used as antispas-
modic, antirheumatic (topical use), anti-inflammatory
[6,7], antinociceptive [8], hypoglycemiant and abortifa-
cient [9,10]. Also there are reports describing the plant
with sudorific, anti-venereal, diuretic, sedative, anti-
helminthic, emmenagogue, anesthetic and depurative
[6,9] properties. In some South American countries, alco-
hol and water infusions have been used in patients with
leukemia and breast cancer having good efficacy and rea-
sonable toxicity at higher doses than commonly used by
folk medicine [11-13].
Compounds isolated and reported for Petiveria alliacea
includes flavonoids as astilbin, myricitrin, engeletin, trit-
erpenes as barbinervic acid, α-friedelinol, steroids as dau-
costerol, lipids as lignoceric acid, nonadecanoic acid, oleic
acid, compounds as allantoin, coumarin, [14-16], and
several sulfur-containing amino acids in the roots; as well
as S-benzylcysteine sulfoxides, and S-(2-hydroxyethyl)
cysteine sulfoxides [17,18]. It is likely that benzylcysteine
sulfoxides serve as precursors to thiosulfinates as S-(2-
hydroxyethyl)-phenylmethanethiosulfinate and sulfines
as thiobenzaldehyde S-oxide. Isolation and identification
of three glutamyl dipeptides from roots of this plant have
also been reported [19]. Dibenzyl trisulphide (DTS), a
lipophilic compound found in the plant and identified as
one of the immunomodulatory compounds [20], exhibit-
ing anti-proliferative and cytotoxic activity were the
cytoskeleton is implicated [21].
Several reports describe phytochemical characterization
of  Petiveria alliacea's ethanol and aqueous extracts,
[11,14,16,17,22], and ethnopharmacological evidence
describing possible antitumor activity [11]. This learning
has not been immersed into common medical practice
because lack of reliable experimental data. The present
study examines cytotoxic activity in vitro of a partially
purified Petiveria alliacea fraction over several tumor cell
lines. Results warrant to continue toxicological and phar-
macological testing that could lead to a role in tumor
treatment.
For decades, pharmacognostic and ethnobotanical studies
have focused in the search of single plant drug isolation,
assuming that one drug is responsible for all plant biolog-
ical activity. However, western medicine and even
ayurveda, considers the possibility of synergy between dif-
ferent components in phytomedicine. Furthermore, there
are clear examples where a single isolated compound is
unable to reproduce the plant extract activity [23].
Current technical development in "omics" technology has
permitted development of gene expression signatures for
plant specific fractions. The latter technical advance
allows validation of traditional plant uses, but unfortu-
nately due to the high costs turns to be a technology quite
inaccessible for developing countries. The present study,
in addition to partial characterization of the plant frac-
tion, we evaluate "protein expression signature" over
melanoma tumor cells [24].
Methods
Petiveria alliacea fraction preparation
Plant material was collected in Viota, Cundinamarca,
Colombia, and identified by Antonio Luis Mejia (botani-
cal consultant) as Petiveria alliacea Linne. Plant material
was compared with the Herbario Nacional Colombiano
sample, registry number 333406 of August 12 de 1991.
Dry ground leaves and stems (300 g) from Petiveria allia-
cea were extracted under reflux (60°C) with 1.5 liter of
96% ethanol for 3 h. The ethanol extract was filtered and
evaporated until half its volume. An equal volume of
water was added and heated (65°C) for 20 minutes to
allow flocculation. The precipitate was eliminated by fil-
tration and the liquid part subjected to liquid-liquid
extraction with ethyl acetate (EtOAc) seven times. All the
EtOAc fractions were combined and taken to dryness at
40°C under vacuum conditions. The dry extract was sub-
mitted to column chromatography on RP-C18 column
(30 × 4 cm), and mobile phase methanol: water
(MeOH:H2O). For ratio (1:1), 600 ml were eluted, yield-
ing F-1 to F3 fractions. F-4 fraction eluted within the first
150 ml of ratio (7:3), and F-5 to F11 fractions eluted from
the last 450 ml of ratio (7:3) and (9:1). F-1 to F11 frac-
tions were assayed at concentrations ranging from 125 to
1.9 μg/ml but only fraction named F4 exhibited high cyto-
toxicity causing relevant changes in tumor cell lines mor-
phology, reason why the biological testing was carryout
on F4 fraction.
Cell lines and growth conditions
Mel-Rel was established as a melanoma cell line from
tumors developed in REL transgenic mice (gift from Dr.
Armell Prevost, Cohin Hospital, Paris, France). A375 are
human melanoma cells, courtesy of the Instituto de Inves-
tigaciones de la Universidad del Rosario (Bogotá, Colom-
bia) and K562 a human erythroleukemia cell line from
ATCC. Cells were placed in RPMI-1640 supplemented
medium (10% FBS, 2 mM L-glutamine, 100 U/ml penicil-
lin, 100 μg/ml streptomycin, 0.01 M Hepes) and incu-BMC Complementary and Alternative Medicine 2008, 8:60 http://www.biomedcentral.com/1472-6882/8/60
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bated under humidified environment at 37°C and 5%
CO2. Adherent cells at 75% of confluence were detached
(trypsin/EDTA), washed (PBS) and suspended in com-
plete medium. Human peripheral blood mononuclear
cells (PBMC) from healthy volunteers were separated by
density gradient centrifugation (Ficoll-Hypaque, Amer-
sham, Biosciences) and the human fibroblasts from gingi-
val tissue of healthy volunteers. PBMC and human
fibroblasts were suspended in RPMI-1640 supplemented
medium (10% FBS, 2 mM L-glutamine, 100 U/ml penicil-
lin, 100 μg/ml streptomycin, 0.01 M Hepes) and incu-
bated under humidified environment at 37°C and 5%
CO2.
In vitro cytotoxicity (IC50) and normal cell assays
All tumor cell lines were incubated and treated with F4
fraction (125 to 1.9 μg/ml), ethanol (0.2%), as negative
control and vincristine (0.1 to 0.0015 μg/ml) as positive
control, during 48 h at 37°C. Adherent cells trypsinized,
and washed with saline phosphate buffer (PBS). Human
PBMC and fibroblasts were seeded (2 × 105 cells/well) on
96-well plates and incubated with or without phytohe-
magglutinin (PHA, GibcoBRL) for 12 h. Afterwards,
PBMC and fibroblasts were treated with F4 fraction (125
to 1.9 μg/ml), ethanol (0.2%) and vincristine, for 60 h
and 24 h, respectively. After treatment cells were centri-
fuged, F4 fraction removed and lastly cells were carefully
washed 3 times (PBS) before adding the MTT. Next 12 μl
of MTT 12 mM [3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyl tetrazolium bromide] (Molecular Probes, Eugene,
Oregon, USA) in PBS was added to each well and incu-
bated for 4 h at 37°C. Formazan crystals were dissolved
with SDS-HCl 0.01 M. MTT results were read at 540 nm in
a Multiskan MCC/340 (LabSystems). In addition cell via-
bility was assessed with a trypan blue dye exclusion test.
The IC50 (50% inhibition of cell growth) value was calcu-
lated using Probit analysis (MINITAB® Release 14.1. Min-
itab Inc. 2003 Statistical Software).
Cell cycle analysis
Mel Rel, A375 and K562 tumor cells lines, starved for 72
h (to induce arrest in G1 phase), seeded in 12-well plate
(4 × 105 cells/well) were treated with concentrations of F4
fraction at 12, 18, 24 and 48 h under humidified environ-
ment at 37°C and 5% CO2. After treatment, cells were
washed and fixed with ethanol (70%, ice-cold) during 18
h. After fixing, cells were suspended in PBS 1X, 100 U/ml
RNase, 50 μg/ml of propidium iodide (Sigma, St. Louis,
MO) and incubated at room temperature for 30 min. Cell
DNA content was measured by flow cytometry using a
FACScalibur, (Becton Dickinson, Fullerton, CA). For cyto-
metric data 50,000 cellular events were collected per sam-
ple and analyzed with Cell Quest software (Becton
Dickinson). Cell cycle distribution percentages are calcu-
lated by Modfit LT software. FACScalibur calibration is
performed with the DNA QC Particle Kit (Becton Dickin-
son). Treatments were performed in triplicate, and results
express as mean ± SEM.
Cytoskeleton organization analysis
A375 human cells (5 × 104 cells/ml) plated on glass cov-
erslides (13 mm diameter), precoated with collagen
(Sigma, St. Louis, MO) were allowed to adhere for 16 h.
Afterwards, treated with F4 fraction for 24 h and incu-
bated under humidified environment, at 37°C and 5%
CO2. Treated cells were washed (PBS) and fixed (2% para-
formaldehyde in PBS) for 30 min at 4°C. Fixed cells were
wash twice with 1% PBS-BSA, incubated with cold ace-
tone for 1 min, washed (1% PBS-BSA) and incubated with
phalloidin conjugated to Oregon-green (Molecular
Probes, Eugene, Oregon, USA), diluted in 1% PBS-BSA (1/
40) for 30 min. Slides were mounted with prolong anti-
fade kit (Molecular Probes, Eugene, Oregon, USA) and
analyzed under fluorescence microscope (Olympus,
Japan).
DNA fragmentation analysis
A375 human cells were treated and incubated as
described on cytoskeleton organization procedures except
for last step were cells are stained with 300 nM of DAPI
(Sigma, St. Louis, MO) for 5 min. Slides were mounted
with prolong anti-fade kit (Molecular Probes, Eugene,
Oregon, USA) and cells analyzed under fluorescence
microscope (Olympus, Japan).
Clonogenic assays
K562 human cells (2.5 × 105 cells/well) plated (96-well
plate) were treated with F4 fraction at 31.2, 15.6 and 7.8
μg/ml, or 200 μg/ml etoposide, or 0.1 μg/ml vincristine or
0.2% ethanol (in PBS) and incubated for 24 h under
humidified environment at 37°C and 5% CO2. After treat-
ment cells were re-plated onto 0.5% agar dishes (60-mm,
20,000 cells/dish), incubated for 14 days (37°C and 5%
CO2) and stained with violet crystal (0.4% in ethanol).
Cell colonies with more than 50 cells were counted. Treat-
ments were performed in triplicate, and results expressed
as mean ± SEM.
Evaluation of Mitochondrial Membrane potential (MMP)
Mitochondria membrane potential (MMP) was measured
on human K562 cells by flow cytometry, using JC-1, a
lipophilic cationic probe (5,5',6,6'-tetrachloro-1,1',3,3'-
tetraethyl-benzimidazolcarbocyanine iodide), (Sigma, St.
Louis, MO). JC-1 (10 μg/ml in PBS) is added to 3 × 105
cells/ml and incubated for 10 min at 37°C. Data analysis
was processed by Cell Quest software (Becton Dickinson).
All treatments were performed in triplicate, and results
expressed as mean ± SEM.BMC Complementary and Alternative Medicine 2008, 8:60 http://www.biomedcentral.com/1472-6882/8/60
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Characterization and identification of proteins
Sample Preparation
A375 cells treated with F4 fraction (31.2 μg/ml for 24 h)
lysed in lysis buffer, supplemented with phosphatase and
proteinase inhibitors. Protein samples were de-salted in
10 K microcon, diluted with 100 ml of ammonium bicar-
bonate buffer (100 mM). Cysteine residues were reduced
with DTT (10 mM) by incubation at 65°C for 45 min.
After cooling to room temperature, sulfhydryls were
alkylated with iodoacetamide (55 mM) for 30 min at
room temperature in a dark environment. The reduced
and alkylated sample was diluted (1:1) with water.
Trypsin (Promega, Madison, WI) was added at a 1:50
enzyme:substrate ratio, and incubated overnight at 37°C.
Tryptic peptides were completely dried in a SpeedVac and
reconstituted with 10 ml of 0.1% TFA.
HPLC-Chip/MS analysis
A 1 ml sample of peptides was injected onto an LC/MS
system consisting of an 1100 Series liquid chromato-
graph, HPLC-Chip Cube MS interface, and 1100 Series
LC/MSD Trap XCT Ultra ion trap mass spectrometer (all
Agilent Technologies). The system is equipped with an
HPLC-Chip (Agilent Technologies) that incorporated a
40-nl enrichment column and a 43-mm × 75-mm analyt-
ical column packed with Zorbax 300SB-C18 5-mm parti-
cles. Peptides were loaded onto the enrichment column
with 97% solvent A (water with 0.1% formic acid). They
were then eluted with a gradient from 3% B (acetonitrile
with 0.1% formic acid) to 45% B in 25 min, followed by
a steep gradient to 90% B in 5 min at a flow rate of 0.3 ml/
min. The total runtime, including column reconditioning,
was 35 min. The column effluent was directly coupled to
an LC/MSD Trap XCT Ultra ion trap mass spectrometer
(Agilent Technologies) via a HPLC-Chip Cube nanospray
source operated at ~1900 volts in ultra-ultra mode. The
gain control (ICC) was set to 500000 with a maximum
accumulation time of 150 milliseconds. CID was triggered
on the six most abundant, not singly charged peptide ions
in the m/z range of 450–1500. Precursors were set in an
exclusion list for 1 min after two MS/MS spectra.
Data analysis
CID data was searched against the SwissProt all species
database, using the Agilent Spectrum Mill Server software
(Rev A.03.03.) installed on a HP Intel® Xeon (TM) dual
processor server. Peak lists were created with the Spectrum
Mill Data Extractor program with the following attributed:
scans with the same precursor ± 1.4 m/z were merged
within a time frame of ± 15 s. Precursor ions needed to
have a minimum signal to noise value of 25. Charges up
to a maximum of 7 were assigned to the precursor ion,
and the 12C peak was determined by the Data Extractor.
The SwissProt database was searched for tryptic peptides
with a mass tolerance of ± 2.5 Da for the precursor ions
and a tolerance of ± 0.7 Da for the fragment ions. Two
missed cleavages were allowed. A Spectrum Mill auto-val-
idation was first performed in the protein details, fol-
lowed by peptide mode using default values [Minimum
scores, minimum scored peak intensity (SPI), forward
minus reversed score threshold, and rank 1 minus rank 2
score threshold]. All protein hits found in a distinct data-
base search by Spectrum Mill were non-redundant. Anal-
ysis of the increase or decrease in proteins was performed
by comparing each sample with the control. Those values
above and below 0.250 from the control value were con-
sidered up- or down-regulated.
HPLC-PDA MALDI-TOF
HPLC chromatogram was recorded on a Waters HPLC
Alliance 2690 (Waters, Milford, MA) chromatograph with
PDA detector (Waters 2690), and RP-C18 column (5 μm,
2.1 × 150 mm, Waters), at 0.3 ml/min with acetonitrile-
water (4:6). MALDI-TOF spectra was recorded in a mass
spectrometer (Bruker Reflex III), equipped with a 337 nm
N2 laser and HCCA matrix.
Statistical analysis
The mean fluorescent intensity was used to compare flow
cytometry data of controls and samples and expressed as
the mean ± SEM. The unpaired Student's t-test was used (p
< 0.05) to measure differences between treatments and
controls. IC50 was estimated using Minitab 14 Statistical
Software Probit analysis [(MINITAB® Release 14.1. Min-
itab Inc. 2003 Statistical Software).
Results
F4 fraction Characterization
Fig. 1A shows 7 peaks. Peak 2 and 3 accounts for approx-
imately 60% of total area. Maximum absorption λ
(lamda) for peak 2 is 278 nm, and for peak 3, 266 and 319
nm. Peak 6 accounts for 12% of the total area, with maxi-
mum absorption λ at 284 nm. Peaks 1, 4, 5 and 7 inde-
pendently, exhibit lower percentages, but combined
account for 27% of the total fraction. Peaks maximum
absorption λ are 279, 285, 317 and 316 nm, respectively.
Fig. 1B shows F4 fraction mass spectra profile including
10 peaks with the following mass/charge (m/z) ratios:
140, 193, 206, 213, 219, 272, 329, 340, 369, and 468. The
HCCA peaks correspond to matrix (4-cyano-4 hydroxy-
cinnamic acid) signals. Peaks with m/z of 340 and 369
have the higher concentrations, while peaks of m/z ratios
140, 193 and 206 reveal intermediate concentrations.
Peaks with m/z ratios of 213, 219, 272, 329 and 468 have
the lowest concentrations. Fig. 1C shows possible com-
pounds present in F4 fraction with their corresponding
molecular masses. Compound identification accomplish
by matching the MALDI-TOF m/z with molecular weights
of compounds previously reported for Petiveria  [14-
17,22]. The m/z ratio given by MALDI-TOF spectra com-
prises a deviation range of ± 7 mass units, due to the
method used. This difference was taken into account forBMC Complementary and Alternative Medicine 2008, 8:60 http://www.biomedcentral.com/1472-6882/8/60
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Petiveria alliacea F4 fraction characterization Figure 1
Petiveria alliacea F4 fraction characterization. A. Upper panel shows compound UV spectra and retention time. Lower 
panel shows peak area and retention time. B. F4 fraction was subjected to MALDI-TOF-MS analysis. Numbers above the peaks 
correspond to m/z ratios. The horizontal axis represents the mean relative intensity and the abscissa m/z ratios. HCCA peaks 
correspond to matrix (4-cyano-4 hydroxy-cinnamic acid) signals. C. m/z ratio of compounds reported for Petiveria and com-
pounds found in F4 fraction matching within (± 7) units of the m/z ratio.BMC Complementary and Alternative Medicine 2008, 8:60 http://www.biomedcentral.com/1472-6882/8/60
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compound identification. The observed peak (m/z = 140)
represents three possible compounds: thiobenzaldehyde-
S-oxide, 1,2 diisothiocyanato ethane (senfol) and cou-
marin, with molecular masses of 139, 144 and 146 respec-
tively. The peak of m/z = 193 probably corresponds to
pinitol (194), and peak 206, no compounds matching
that m/z ratio are reported for Petiveria alliacea. Peaks with
m/z of 213, 219 and 272 respectively, correspond to sul-
fur compounds: dibenzyl sulfide, S-(2-hydroxyethyl)-
phenylmethanethiosulfinate and for peak 272 two com-
pounds; 3,5-diphenyltritiolan (276) and dibenzyltri-
sulfide (278). A m/z of 329 corresponds to flavonoid 5-O-
methyl leridol, while a m/z of 340 has two possible com-
pounds 4-ethyl petiveral and glutamyl-S-benzyl cysteine.
Finally peaks 369 and 468 correspond to lignoceric acid
and myricitrin respectively. Since compound identifica-
tion was carry out comparing m/z ratio calculated by
MALDI-TOF with the reported m/z ratios, identification
of stereoisomers by this approach is not feasible. Based on
m/z ratios, the compounds described for the F4 fraction
are thought to be those presented. However, definitive
identification is underway.
Petiveria alliacea F4 fraction induces morphological 
changes on tumor cell lines without affecting normal 
human cells
F4 fraction cytotoxic activity evaluated by MTT assay is
shown on figures 2A, B and 2C. The cytotoxicity of F4 frac-
tion is dose dependent inducing significant morphological
changes, as cell deformation and elongation in similar way
to vincristine in all tested tumor cell lines (Fig. 3A). Accord-
ing to IC50, F4 fraction shows similar cytotoxic potency on
A375, Mel Rel and K562 tumor cells lines with values of
35,2, 36,3 and 32,0 μg/ml respectively (Table 1). Comparing
cytotoxic activity between tumor cell lines and normal
human cells, F4 fraction exhibits significantly less cytotoxic-
ity on normal fibroblasts (IC50 440 μg/ml) (Fig. 2D and
Table 1) or human mononuclear cells with or without phy-
tohemaglutinin (PHA) (IC50 151, 121 μg/ml respectively)
(Fig. 2E, F and Table 1). F4 fraction is by far the most prom-
ising fraction owing significant difference in cytotoxicity for
tumor cell lines as compared with normal cells, explaining
the reason why F4 fraction was extensively studied.
In addition, we observed that tumor cells treated with F4
fraction underwent morphological changes in shape,
adhesion ability and induced G2 phase arrest. To further
study F4 fraction activity on actin cytoskeleton organiza-
tion, cells treated with F4 fraction were stained with phal-
loidin-oregon green conjugate. As observed in Fig. 3B,
actin cytoskeleton organization was disturbed after 24
hours. A375 cells treated with F4 fraction did not show
the same fluorescence pattern as observed in control cells
(ethanol 0.2%). Vehicle cells showed considerable F-actin
cytoskeleton organization (Fig. 3B; left panel), while cells
treated with F4 fraction showed differences in shape, dis-
playing reorganized filamentous structures (Fig. 3B; mid-
dle and right panels). The latter indicates that actin
filaments were transformed into actin granules confining
at the cell sub-membrane area. Similar results were
obtained with cell line Mel-Rel (data not shown).
F4 fraction induces apoptosis in a mitochondria 
independent way
Antitumor drugs commonly induce apoptosis via mito-
chondria, liberating cytochrome c, activating endonucle-
ases, and ending in DNA fragmentation. However, F4
fraction did not induce mitochondrial membrane depo-
larization in K562 cells, contrasting with the behavior
shown by S2 fraction (positive control used), which is
also a Petiveria alliacea fraction that induces mitochon-
drial depolarization (Fig. 4A). Nonetheless, F4 fraction
instead stimulates endonuclease activation and DNA frag-
mentation shown by staining with DAPI and analyzed by
fluorescence microscopy on A375 cells (Fig. 4B). This sug-
gests that F4 fraction activates effector caspases in a mito-
chondria independent pathway.
Effect of F4 fraction on tumor cell cycle distribution
To further study the effect of F4 fraction on tumor cell
lines, cell cycle distribution was assessed on A375, K562,
and Mel-Rel cell lines by flow cytometry, staining the
DNA content with propidium iodide. Cells treated with a
single dose of F4 fraction (31.2 μg/ml) induced G2 arrest
(60%) as compared with a negative control (18%) etha-
nol (0.2%). Vincristine (0.1 μg/ml), positive control
induced G2 arrest (80%) as shown on Fig. 5A. K562 and
Mel Rel behave in the same manner (data not shown). In
addition, F4 fraction activity over cell cycle kinetics was
further investigated, by synchronizing A375 cells in a
pulse chase experiment over 48 h. The G2 arrest in A375
cells lasts 48 h as shown in Fig. 5B. The G2 arrest was pro-
Table 1: Comparative IC50 values of F4 fraction and vincristine over tumor cell lines and normal human cells.
CELLS A375 K562 Mel Rel PBMC no PHA PBMC with PHA Fibroblasts
F4 fraction (IC50 μg/ml) 35.2 ± 1.35* 32 ± 1.41 36.3 ± 1.64. 121 ± 2.6 * 151 ± 8.3 * 440 ± 15 *
Vincristine (IC50 nM) 132 ± 10* 61 ± 4* 124.5 ± 15* 247 ± 22* 197 ± 20* 85.5 ± 24*
± = SEM, p < 0.05
The IC50 values of tumor cell lines and normal human cells treated with F4 fraction were calculated with Minitab 14 Statistical Software Probit 
analysis. The values are mean ± SEM from three independent experiments.BMC Complementary and Alternative Medicine 2008, 8:60 http://www.biomedcentral.com/1472-6882/8/60
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duce at 31.2 and 15.6 μg/ml but not at higher concentra-
tions (Fig. 5C).
F4 fraction reduces tumor cells clonogenic survival
K562 human cell line treated with F4 fraction significantly
reduced cell colony formation, as compared with vehicle
cells (0.2% ethanol). Colonies were evaluated after 14
days of treatment (Fig. 6) and a decrease in clonogenic
survival was observed in treated cells as compared to a
negative control (0.2% ethanol). However, the decrease in
clonogenic survival exhibited by positive controls, etopo-
side (100 μg/ml) and vincristine (0.1 μg/ml) was slightly
greater. Similar data was observed on A375 cells (data not
shown).
Petiveria alliacea F4 fraction is cytotoxic to tumor cell lines without affecting human normal cells Figure 2
Petiveria alliacea F4 fraction is cytotoxic to tumor cell lines without affecting human normal cells. A. A375 B. Mel 
Rel C. K562 D. Human fibroblasts E. PBMC stimulated with PHA or F. PBMC-PBS treated with F4 fraction concentrations 
(white) at 125 (1), 62.5 (2), 31.2 (3), 15.6 (4), 7.8 (5), 3.9 (6), and 1.8 μg/ml (7); or vincristine (black) 0.1 (1), 0.05 (2), 0.025 (3), 
0.0125 (4) 0.00625 (5), 0.0031 (6) and 0.0015 μg/ml (7), for 24 h. Cell viability was determined by MTT assay as described in 
the methods section. Data represent cell viability percentage (%), where the vehicle-treated cells are regarded as 100%. The 
values are mean ± SEM from three independent experiments.BMC Complementary and Alternative Medicine 2008, 8:60 http://www.biomedcentral.com/1472-6882/8/60
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Proteomic characterization of F4 fraction activity over 
tumor cells
To better understand the mechanism by which F4 fraction
exerts its cytotoxic activity on tumor cell lines, A375
(human) cells were treated with F4 fraction (15 and 31.2
μg/ml) or ethanol (0.2%) (negative control) for 24 hours.
The protein content was analyzed by mass spectrometry.
Experimental analysis demonstrated that various proteins
were either up- or down-regulated (Table 2 and 3). Out of
201 proteins 76 were up-regulated, 114 were down-regu-
lated and 11 remained unchanged. Ribosomal proteins
(e.g., ribosomal protein L4, 5, 7a, 8, 9, 10, 10a, 11, 12, 13,
14, 18, 18a, 19, 23, 26, 27, 27a, 28, 32, 36, 37a, ribosomal
protein S2, 4, 5, 6, 8, 11, 12, 13, 15a, 18, 19, 24, 25, 27,
31 and ribosomal protein P0 variant) are molecules
important for tumor growth and survival. Cytoskeleton
proteins (e.g., lamin B1, dynein light chain 1, plectin, t-
complex polypeptide 1 (TCP-1), chaperonin containing
TCP-1 (subunit 6 A and 7), kinesin, tubulin alpha 6,
myosin heavy polypeptide 9, actin, gamma 1 propeptide,
adenylyl cyclase-associated protein, F-actin capping pro-
tein alpha 1, Miller-Dieker lissencephaly protein, myosin,
light polypeptide 6B, alkali, smooth muscle and non-
muscle, (isoform CRA) are also down-regulated.
Efficiency in synthesis of cytoskeleton proteins is required
for tumor colony formation, partly explaining why treat-
ment with F4 cells cannot form colonies in soft agar. In
addition, these results explain why morphology of treated
cells is also abhorrent under light microscope. Also treat-
ment of tumor cell lines with F4 fraction affected proteins
associated with metabolism (e.g., peroxiredoxin 6, glu-
cose phosphate isomerase, ACLY variant protein, phos-
phoglycerate dehydrogenase, pyruvate kinase, muscle
isoform CRA, enolase 1, variant Fatty acid synthase, lac-
tate dehydrogenase A, phosphoglicerate kinase (PGK),
F4 fraction induces morphological changes in tumor cells Figure 3
F4 fraction induces morphological changes in tumor cells. A. A375 cells treated with ethanol 0.2% (left panel), vincris-
tine 0.1 μg/ml (middle panel) or F4 fraction 31.2 μg/ml (right panel). Morphological changes were analyzed under invert micro-
scope. Results represent three independent performed experiments. B. A375 (104) treated with ethanol 0.2% (left panel) or F4 
fraction 31.2 μg/ml (middle and right panels) for 24 h. Cells were stained with Oregon Green-phalloidin were analyzed under 
fluorescent microscope. Results show photos representing four independent experiments.BMC Complementary and Alternative Medicine 2008, 8:60 http://www.biomedcentral.com/1472-6882/8/60
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F4 fraction has no activity on mitochondrial membrane depolarization Figure 4
F4 fraction has no activity on mitochondrial membrane depolarization. A. K562 human cells were treated with F4 
fraction (31.2 μg/ml), or positive control S2 fraction (15.6 μg/ml) or ethanol (0.2%) for 4, 8 and 12 h. All cells were stained with 
JC-1 (Sigma) dye and analyzed by flow cytometry (FACScalibur CellQuest software program) (Becton Dickinson). Bars repre-
sent cell percentage (%) ± SEM of depolarized (filled bars) or non-depolarized (hatched bars) cells, representing two independ-
ent experiments. ***p < 0.001 versus control (ethanol 0.2%; Unpaired Student's t-test). B. A375 cells treated with ethanol 
(0.2%) (left panel) or F4 fraction (31.2 μg/ml) (right panel) for 24 h were permeabilized, stained with DAPI and analyzed under 
fluorescence microscope (Olympus). Results show photos representing four independent experiments.BMC Complementary and Alternative Medicine 2008, 8:60 http://www.biomedcentral.com/1472-6882/8/60
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Effect of Petiveria alliacea F4 fraction on cell cycle Figure 5
Effect of Petiveria alliacea F4 fraction on cell cycle. A. A375 cells treated with ethanol (0.2%), or F4 fraction (31.2 μg/ml) 
or vincristine (0.1 μg/ml) for 24 h, were permeabilized, stained with propidium iodide (PI) 50 μg/ml and analyzed through flow 
cytometry (FACScalibur CellQuest software program) (Becton Dickinson). Bars represent relative percentage of cell-cycle dis-
tribution ± SEM and represent three independent performed experiments. ***p < 0.001 versus control (ethanol 0.2%; 
Unpaired Student's t-test). B. A375 cells treated with ethanol (0.2%) or F4 fraction (31.2 μg/ml) or vincristine 0.1 μg/ml for 12, 
18, 24 and 48 h, were permeabilized, stained with PI 50 μg/ml and analyzed through flow cytometry (FACScalibur CellQuest 
software program) (Becton Dickinson). Histograms represent relative cell DNA content representing two independent exper-
iments. C. A375 cells treated with ethanol (0.2%) or F4 fraction(62.5, 31.2, 15.6 μg/ml) or vincristine (0.1 μg/ml) for 48 h, were 
permeabilized, stained with PI 50 μg/ml and analyzed through flow cytometry (FACScalibur CellQuest software program) (Bec-
ton Dickinson). Histograms represent relative cell DNA content representing two independent experiments.BMC Complementary and Alternative Medicine 2008, 8:60 http://www.biomedcentral.com/1472-6882/8/60
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ATP synthase, H+ transporting, mitochondrial F1 com-
plex, beta subunit precursor, glyceraldehyde-3-phosphate
dehydrogenase, glucosidase II, prostaglandin E synthase 3
(cytosolic), dihydropyrimidinase-like 2 variant); some
were drastically down-regulated, while others were greatly
up-regulated. Chaperone proteins (e.g., Hsp70, Hsp60,
tumor rejection antigen (gp96), Hsp90, Hsp90alpha)
were also down-regulated after F4 fraction treatment;
these proteins are critical for cell survival and protection
from stressful stimuli.
Discussion
Significant attained information from ethnopharmaco-
logical reports for our study is the Petiveria alliacea's anti-
tumor and immunomodulatory reported activities. To
date at a molecular level, there is a lack of scientific evi-
dence to explain such activities. For example, a meth-
anolic extract was unable to induce cytotoxicity on Hep
G2 cells. Nonetheless, no specific reason was given for the
lack activity in this case [25]. Several compounds isolated
from Petiveria alliacea, such as astilbin and dibenzyl trisul-
phide have been demonstrated to induce apoptosis or
influence cell cycle or affect actin dynamics [20,26]. The
present study demonstrates that Petiveria alliacea's F4 frac-
tion contains substances capable of inducing G2 arrest in
a dose and time dependent manner (Fig. 5). The ability of
F4 fraction to change cell morphology and induce G2
arrest was further investigated. Previous reports demon-
strate that dibenzyl trisulphide (DTS), one of the sulfur
compounds found in Petiveria alliacea, might be responsi-
ble for this dual activity [20]. DTS has been previously
reported to exhibit potent immunomodulatory function,
capable of increasing murine thymic weight along with
up-regulation of parameters associated with the reticu-
loendothelial system, a system essential for molecules
involved in immunomodulatory functions [23]. Mice
exposed to lethal dose of E. coli were protected from death
probably because an increase in phagocytic activity
[27,28]. DTS has also been reported having anti-fungal
activity in vitro [16], as well as insecticidal, acaricidal and
insect repellent activities in vivo [29].
DTS causes reversible microtubule disassembly, which
may be due to attenuation of the tyrosyl residues dephos-
phorylation of the MAP kinases (erk1/erk2) [20]. Along
with the fact that MAP kinases are involved in develop-
ment and apoptotic responses, this event suggests a
molecular linkage between these two observations.
Mixed-lineage kinase 3 (MLK-3, a kinase of the family
controlling MAP kinases activity) inhibition, can cause
mitotic arrest by a mechanism involving disruption of
microtubule formation and spindle pole assembly [30].
The latter data indicates that Petiveria alliacea F4 fraction
might inhibit MLK3.
Presence of apoptotic cells after treatment with F4 fraction
clearly suggests that cell cycle arrest induces cell death
(Fig. 5A). The F4 fraction from Petiveria alliacea did not
cause mitochondrial membrane depolarization, suggest-
ing that cell death is caused by mitochondrial independ-
ent mechanisms (Fig. 4A and 4B). Differentiation of cell
death mechanisms, such as necrosis or apoptosis, become
necessary since an inflammatory response after tissue
injury might be different. The induction of an immune
response in situ could be the consequence of equilibrium
between apoptosis and subsequent necrotic death.
The types of compounds tentatively found in Petiveria
alliacea's F4 fraction are sulfur compounds, flavonoids,
flavonoid glycosides, coumarin, a monomethylated cyclo
hexitol and a fatty acid. The sulfur compounds reported
for Petiveria alliacea and probably present in F4 fraction
are: thiobenzaldehyde S-oxide, dibenzyl sulfide, S-(2-
hydroxiethyl)-phenylmetanethiosulfinate, glutamyl-S-
benzyl cysteine and dibenzyltrisulfide (Fig. 1B y 1C). It is
likely that these compounds are produced by petiverins
(benzyl sulfoxides) degradation during the plant extrac-
tion process [31], and are associated with antitumor activ-
ity. Dibenzyl trisulfide, an immunomodulatory
compound isolated from Petiveria [20,21], is likely to be
present in our fraction. Therefore, could be one of the
compounds responsible for the biological activity present
F4 fraction abrogates K562 erythroleukemic cells colony  forming ability Figure 6
F4 fraction abrogates K562 erythroleukemic cells 
colony forming ability. K562 cells plated at 2.5 × 105 cells/
well were treated with ethanol (0.2%), or F4 fraction (from 
7.8 to 31.2 μg/ml), or etoposide (100 μg/ml), or vincristine 
(0.1 μg/ml) for 24 h. Afterwards, cells were stained with 
crystal violet (0.4% in ethanol). Data represents number of 
colonies ± SEM representing two independent experiments. 
***p < 0.001 versus control (ethanol 0.2%) Unpaired Stu-
dent's t-test).BMC Complementary and Alternative Medicine 2008, 8:60 http://www.biomedcentral.com/1472-6882/8/60
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Table 2: Proteins down regulated by F4 Fraction
Down regulated proteins Accesion Number
Translation
Asparaginyl-tRNA synthetase NP_004530
BAT1 protein BAF31287
CGI-74 protein AAD34069
Dhx9 (DEAH) P-9, RNA Helicasa A (RHA)/DEAH (Asp-Glu-Ala-His) NP_001348
Eukariotic translation elongation factor 1 gamma AAH13918
Eukariotic translation elongation factor-2 (EF-2). NP_001952
Eukaryotic initiation factor 4A (eIF-4A) NP_001407
Heparin-binding protein HBp15 solo un articulo AAP97261
Heterogeneous nuclear ribonucleoprotein H1 NP_005511
Heterogeneous nuclear ribonucleoprotein U isoform a (scaffold attachment factor-A) NP_114032
Interleukin enhancer binding factor 3, 90 Kda EAW84137
Nucleolin NP_005372
Nucleosome assembly protein 1-like 1 NP_631946
Poly(rC)-binding protein 2 isoform b variant PCBP2 NP_114336
Small nuclear ribonucleoprotein Sm D1 CAE11897
Tryptophanyl-tRNA synthetase (IFP53) CAA44450
Tu-transcription elongation factor. ET-1 o EF-Tu NP_003312
Transcription processing
CGI-74 AAD34069
DEAD (Asp-Glu-Ala-His) box polypeptide 21 NP_004719
DEAD (Asp-Glu-Ala-His) box polypeptide 9 NP_001348
Ribosomal Proteins
Ribosomal protein L4 NP_000959
Ribosomal protein L5 EAW73088
Ribosomal protein L7a EAW88064
Ribosomal protein L8 NP_000964
Ribosomal protein L9 NP_000652
Ribosomal protein L10 NP_006004
Ribosomal protein L10a NP_009035
Ribosomal protein L11 NP_000966
Ribosomal protein L12 BAD92708
Ribosomal protein L13 NP_150254
Ribosomal protein L13a AAQ13495
Ribosomal protein L14 NP_004964
Ribosomal protein L18 NP_000970
Ribosomal protein L18a XP_943475
Ribosomal protein L19 EAW60568
Ribosomal protein L23 NP_000969
Ribosomal protein L26 NP_001087230
Ribosomal protein L27 NP_000979
Ribosomal protein L27a NP_001083056
Ribosomal protein L28 NP_000982
Ribosomal protein L31 NP_000984
Ribosomal protein L32 NP_000985
Ribosomal protein L36 NP_378669
Ribosomal protein L37a NP_000989
Ribosomal protein S2 NP_002943
Ribosomal protein S4 EAW71815
Ribosomal protein S5 BAD93040
Ribosomal protein S6 NP_001001
Ribosomal protein S8 EAX07023
Ribosomal protein S11 NP_001006
Ribosomal protein S12 EAW54624
Ribosomal protein S13 NP_001008
Ribosomal protein S15a EAW50259
Ribosomal protein S18 NP_001087248BMC Complementary and Alternative Medicine 2008, 8:60 http://www.biomedcentral.com/1472-6882/8/60
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Ribosomal protein S19 NP_001013
Ribosomal protein S24 EAW54624
Ribosomal protein S25 NP_001019
Ribosomal protein S27 EAW91426
Ribosomal protein P0 variant BAD96291
Replication 
CSE1 chromosome segregation 1-like protein NP_001307
ErbB3 (HER3) binding protein 1 NP_006182
Nucleolin NP_005372
Protein Kinase, DNA-activated, catalytic polypeptide isoform 1 NP_008835
Degradation Proteins
26S proteasome subunit p45 BAA07919
Flap structure-specific endonuclease 1 NP_004102
Fumarate hydratase, isoform CRA_b EAW70091
Histone cluster 1, H1d NP_005311
HMG-1 BAA09924
Hydroxysteroid (17-beta) dehydrogenase 10 isoform 1 NP_004484
Mitochondrial acetoacetyl-CoA thiolase BAA01387
PSMC3 protein AAI07805
Transporters
Mitochondrial trifunctional protein, alpha subunit precursor NP_000173
Prohibitin 2 (Phb2) NP_009204
Solute carrier family 25 (SLC25A5 protein) AAH68199
Cytoskeleton
Actin, gamma 1 propeptide NP_001605
Adenylyl cyclase-associated protein NP_006358
Chaperonin containing TCP-1 (subunit 6 A and 7) NP_006420
Dynein light chain 1 NP_003737
F-actin capping protein alpha 1 NP_006126
Kinesin NP_004512
Lamin A/C, isoform CRA_c AAH00511
Lamin B1 NP_005564
Miller-Dieker lissencephaly protein AAL34972
Myosin heavy polypeptide 9 NP_002464
Myosin, light polypeptide 6B, alkali, smooth muscle and non-muscle, isoform CRA_c EAW96898
Plectin NP_958782
t-complex polypeptide 1 (TCP-1) CAA37064
Tubulin alpha 6 NP_116093
Signal Transduction
RAB5C, member RAS oncogene family isoform b NP_004574
Guanine nucleotide binding protein (G-protein) EAW53700
IQ Motif containing GTPase activating protein 1 BAA06123
Prohibitin (PHB) CAG46507
RAN member RAS oncogene familly EAW98517
Chaperones
HSP70-prot 8 NP_006588
HSP60 ABB01006
Tumor rejection antigen (gp96) or Heat schock protein 90 Kda beta CAI64497
Heat shock protein 90 kDa alpha (HSP90) NP_005339
Metabolism
ACLY variant protein BAE06117
ATP synthase, H+ transporting, mitochondrial F1 complex, beta subunit precursor NP_001677
Dihydropyrimidinase-like 2 variant BAD92432
Enolase 1, variant BAD96912
Fatty acid synthase AAA41145
Glucose phosphate isomerase NP_000166
Table 2: Proteins down regulated by F4 Fraction (Continued)BMC Complementary and Alternative Medicine 2008, 8:60 http://www.biomedcentral.com/1472-6882/8/60
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Glucosidase II CAA04006
Glyceraldehyde-3-phosphate dehydrogenase NP_002037
Lactate dehydrogenase A NP_005557
Peroxiredoxin 6 NP_004896
Phosphoglicerate kinase (PGK) NP_000282
Phosphoglycerate dehydrogenase NP_006614
Prostaglandin E synthase 3 (cytosolic) AAH03005
Pyruvate Kinase, muscle isoform CRA_c AAH12811
Tumoral Antigen
Melanoma-associated antigen 4 (MAGE 4 antigen) P43358
Calcium binding proteins
Annexin 5 NP_001145
Annexine A2 isoform 1 NP_001002858
Proteins from A375 human cells treated with F4 or ethanol (0.2%) as negative control were digested, and the extracted peptides injected onto a 
1100 Series HPLC-Chip Cube MS interface, and Agilent 6300 Series Ion Trap Chip-LC-MS/MS system (Agilent Technologies). Data are the proteins 
down regulated by F4 fraction treatment as judged by mass spectrometry.
Table 2: Proteins down regulated by F4 Fraction (Continued)
Table 3: Proteins up regulated by F4 Fraction
Up regulated Proteins Accesion Number
Translational Proteins
Alanyl t-RNA synthetase variant BAD96544
CDA02 (Eukaryotic translation initiation factor 2A) AAK14926
Eukaryotic translation initiation factor 2, subunit 1 alpha, 35 kDa NP_001406
Eukaryotic translation initiation factor 3 subunit A, KIAA0139 BAA09488
GA17 protein (eukaryotic translation initiation factor 3, subunit M) NP_006351
GCN1 general control of amino-acid synthesis 1-like 1, KIAA0219 BAA13209
Leucyl-tRNA synthetase, cytoplasmic, KIAA1352 BAA92590
Methionine adenosyltransferase II, alpha NP_005902
Mitochondrial isoleucine tRNA synthetase NP_060530
Prt1 homolog, Eukaryotic translation initiation factor 3 subunit B AAB42010
Synaptotagmin binding RNA interacting protein, SYNCRIP AAH24283
Transcription processing
DNA-binding protein A (Cold shock domain-containing protein A) P16989
Heterogeneous nuclear ribonucleoprotein M isoform a NP_005959
Small nuclear ribonucleoprotein polypeptide F NP_003086
Small nuclear ribonucleoprotein Sm D1 CAE11897
Ribosomal Proteins
Ribosomal protein S15 NP_001004
Ribosomal protein S9 NP_001009
Ribosomal Protein S3A NP_000996
Protein Degradation
Proteasa de Cisteina del Retículo (ER60) BAA11928
Proteasome 26S ATPase subunit 1 variant BAD96388
Proteasome 26S ATPase subunit 2 NP_002794
Proteasome 26S non-ATPase subunit 11 variant BAD96916
Proteasome 26S non-ATPase subunit 2 variant BAD93080
Putative ubiquitin-conjugating enzyme E2 D3-like protein Q9NTT1
SUMO1 activating enzyme subunit 1 NP_005491
Tripeptidyl peptidase II CAH72178
Ubiquitin-Activating enzime E1 NP_003325
Transporters
Amino acid transporter E16 AAC61479
ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 isoform 1 NP_733765BMC Complementary and Alternative Medicine 2008, 8:60 http://www.biomedcentral.com/1472-6882/8/60
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Coatomer protein complex subunit alpha isoform 1 (Cop I) NP_001091868
Exportin 1 NP_003391
Karyopherin beta 1, Importin subunit beta-1 NP_002256
SEC13-like 1 (S. cerevisiae), isoform CRA_b EAW64078
Signal recognition particle 72 kDa NP_008878
Solute carrier family 25 (mitochondrial carrier, Aralar), member 12 NP_003696
Stomatin AAH10703
Cytoskeleton
Actin related protein 2/3 complex subunit 2 NP_005722
ARP3 actin-related protein 3 homolog NP_005712
Chaperonin containing TCP1-subunit 2 beta EAW97230
Chaperonin containing TCP1-subunit 3 gamma BAD92119
Destrin, isoform a NP_006861
Dynactin 1 isoform 1 NP_004073
Dynamin 1-like, isoform CRA_c EAW88521
Filamin A, FLJ00343 AAF72339
MYO1C variant protein (myosin-I beta) BAE06097
T-complex protein 1 subunit epsilon, KIAA0098 BAA07894
Transgelin-2, KIAA0120 BAA04802
Cell Cycle
Alpha isoform of regulatory subunit A, protein phosphatase 2 NP_055040
Minichromosome maintenance complex component 6 NP_005906
Poly (ADP-ribose) polymerase family, member 1 NP_001609
Regulator of chromosome condensation 1, isoform CRA_c EAX07692
Septin 9, KIAA0991 BAA76835
Signal Transduction
GTP-binding protein PTD004 isoform 1 NP_037473
Phosphofructokinase, platelet, isoform CRA_a EAW86495
Protein kinase C inhibitor protein 1, YWHAZ AAH51814
Chaperones
Calnexin precursor NP_001737
Nucleophosmin AAW67757
Oxygen regulated protein precursor NP_006380
TNF receptor-associated protein 1 variant BAD93042
Metabolism
5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase NP_004035
Acyl-CoA synthetase long-chain family 3 NP_976251
Aldehyde dehydrogenase 18 family, member A1 CAI16766
Alkylglycerone phosphate synthase, isoform CRA_b EAX11058
Carbamoylphosphate synthetase 2/aspartate transcarbamylase/dihydroorotase NP_004332
Dolichyl-diphosphooligosaccharide-protein glycosyltransferase CAH73476
Enoyl Coenzyme A hydratase AAH08906
Glucosamine–fructose-6-phosphate aminotransferase (GFAT 1) Q06210
HMT1 hnRNP methyltransferase-like 2 isoform 1 NP_001527
Human rab GDI BAA03095
Hydroxyacyl-Coenzyme A dehydrogenase AAH14572
Inosine monophosphate dehydrogenase 2, hCG2002013 EAW64946
Ornithine aminotransferase precursor NP_000265
Phosphogluconate dehydrogenase NP_002622
Phosphoribosyl pyrophosphate synthetase 2, PRPS2 NP_002756
RPN2 CAG33180
S-adenosylhomocysteine hydrolase NP_000678
Proteins from A375 human cells treated with F4 or ethanol (0.2%) as negative control were digested, and the extracted peptides injected onto a 
1100 Series HPLC-Chip Cube MS interface, and Agilent 6300 Series Ion Trap Chip-LC-MS/MS system (Agilent Technologies). Data are the proteins 
up regulated by F4 fraction treatment as judged by mass spectrometry.
Table 3: Proteins up regulated by F4 Fraction (Continued)BMC Complementary and Alternative Medicine 2008, 8:60 http://www.biomedcentral.com/1472-6882/8/60
Page 16 of 17
(page number not for citation purposes)
in F4 fraction. Pinitol, a monomethylated cyclohexitol
reported in Petiveria alliacea and possibly present in our
fraction, has been reported to exhibit anti-inflammatory
properties [32], possibly acting on dendritic cells [33].
Myricitrin, a flavonoid glycoside probably present in F4
fraction, has been reported to have analgesic, anti-inflam-
matory and antinociceptive properties [34]. Coumarin,
another compound possibly found in the F4 fraction is
reported to exhibit anti-tumor activity in prostate cancer
models [35], and anti-inflammatory activities [36]. Other
compounds possibly present in F4 fraction, includes sen-
fol (1,2 diisothiocyanato ethane), 3,5 diphenyltritiolan, 4
ethyl petiveral, 5-O-methyl leridol and lignoceric acid
have no literature reports related to anti-tumoral activity.
Down-regulation of cytoskeleton proteins detected by
mass spectrometric analysis is consistent with the
cytoskeleton disruption observed by fluorescent micros-
copy. Moreover, changes in the concentration of proteins
involved in translation and transduction processes, as
well as those involved in cellular metabolism, could
explain the decrease of tumor cells clonogenic ability, as
well as the anti-tumor activity of Petiveria alliacea. Cur-
rently, we are evaluating the coding genes for these pro-
teins in order to determine if the changes are at the
transcriptional level or whether the proteomic results are
a consequence of differential management of the existing
proteins in the tumor cells. The mechanism by which
tumor cells undergo death should be determined. Our
results indicate that there is DNA fragmentation; however,
it is possible that oxidative stress, metabolic changes,
necrosis or senescence are also ways by which tumor cells
may undergo death. In fact, necrotic death can provide the
necessary danger signals to induce dendritic cells activa-
tion, giving anti-tumoral protective immune response
[37]; although other mechanisms can be implied in this
antigen transfer [38,39]. Induction of an effective
immune response is unknown, but possibly Petiveria allia-
cea F4 fraction, can act as Sho-Saiko-to, or Juzen-taiho-to
[40,41], inducing reduction of primary tumors, metasta-
sis, and generating a specific CD8+ CTL responses. Mech-
anisms implied in the process are unknown. However, it
is critical to understand and elucidate the molecular
mechanisms before the plant fraction can be used in the
design of effective cancer drug therapeutics.
Conclusion
In conclusion, our study demonstrates that Petiveria allia-
cea's F4 fraction, exhibits multiple anti-tumoral activities
against human (K562, A375) and mouse (Mel Rel) tumor
cells. F4 fraction exerts G2 cell cycle arrest, induces actin
cytoskeleton reorganization, affects cell morphology,
causes DNA fragmentation and decreases clonogenicity.
Furthermore, our findings indicate that F4 fraction may
use multiple molecular targets to exert its antitumor activ-
ity.
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